Exelixis Clinical Site #39

Porto Alegre, Rio Grande do Sul 90035-903

0 studies enrolling now · 1 studies all time

What they study most

Differentiated Thyroid Cancer

Studies at this site

• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy — Running, not enrolling